Skip to main content

Meritxell Ventura Cots

Institutions of which they are part

Main researcher
Liver Diseases
Vall Hebron Institut de Recerca

Meritxell Ventura Cots

Institutions of which they are part

Main researcher
Liver Diseases
Vall Hebron Institut de Recerca

Projects

Efectos de la administración de albúmina en pacientes cirròticos con encefalopatia hepática

IP: Joan Genescà Ferrer
Collaborators: Meritxell Ventura Cots, Macarena Simon-Talero Horga
Funding agency: Instituto de Salud Carlos III
Funding: 242000
Reference: ICI14/00352
Duration: 01/01/2015 - 30/06/2019

Malalties Hepatobiliars (GRC)

IP: -
Collaborators: Beatriz Minguez Rosique, Immaculada Raurell Saborit, Lluís Viladomiu Catà, Antonio González Fernández, Lluis Castells Fusté, Maria del Mar Riveiro Barciela, Silvia Sauleda Oliveras, Maria Buti Ferret, Josep Quer Sivila, Josep Gregori Font, Maria Nieves Martell Pérez-Alcalde, Damir Garcia Cehic, Juan Ignacio Esteban Mur, Meritxell Ventura Cots, Macarena Simon-Talero Horga, Joan Genescà Ferrer, David Tabernero Caellas
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 65000
Reference: 2014 SGR 421
Duration: 01/01/2014 - 31/12/2016

Progresión de la hipertensión portal: papel del microbioma intestinal como mediador del efecto de la obesidad

IP: -
Collaborators: Meritxell Ventura Cots, Macarena Simon-Talero Horga
Funding agency: Instituto de Salud Carlos III
Funding: 98615
Reference: PI14/00331
Duration: 01/01/2015 - 31/12/2017

Recerca clínica i traslacionals de les complicacions de la cirrosi hepàtica

IP: -
Collaborators: Meritxell Ventura Cots
Funding agency: Instituto de Salud Carlos III
Funding: 72000
Reference: CM11/00171
Duration: 03/01/2012 - 02/01/2014

Related news

Using computed tomography (CT), with or without contrast, it is possible to perform an accurate and safe detection of the disease without the need for biopsies and avoiding the limitations of other non-invasive diagnostic tools.

On World Clinical Trials Day, we highlight some of the studies we have participated in that confirm the efficacy of new drugs, allowing their approval by regulatory agencies.

Preliminary study results confirm that the drug resmetirom reduces the presence of fat, inflammation, cell damage and fibrosis in the liver.

Related professionals

Jose Fernando Rodríguez Palomares

Jose Fernando Rodríguez Palomares

Main researcher
Cardiovascular Diseases
Read more
Muñoz Vaño, Vicent

Muñoz Vaño, Vicent

Research technician
Nephrology and kidney transplantation
Read more
Català Santarrufina, Alba

Català Santarrufina, Alba

Research technician
Cardiovascular Diseases
Read more
Maria Angeles Jiménez Fuentes

Maria Angeles Jiménez Fuentes

Pneumology
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.